Precision
About the company
Quick links:
Contact:
Melissa Florenova, CEO
Email: melissa@florenova.se
Phone: +46 70 779 18 05
Capital need and valuation:
Capital Need: €1,000,000 (first 3 years)
Pre-Money Valuation: Startup
Use of Funds
Primarily product development
Financial forecast
Estimated Turnover 2025/2026: €350,000
Revenue Model: Sales
Previous investments
Founders have invested: €5,000
External investors: €30,000 – grant from Handelsbanken
Additional research funding from Cancerfonden and ThermoFisher Scientific.
Vision and impact
To transform cancer care by delivering innovative, minimally invasive biopsy solutions that combine advanced molecular profiling and AI-driven insights – empowering clinicians to make more accurate treatment decisions (SDG 3 Good Health and well-being).
Risk management
Identified risks: European Health Data Space Regulation (EHDS)
How you manage them: Insights, expertise and partnerships